D
David J. Chaplin
Researcher at Baylor University
Publications - 184
Citations - 9635
David J. Chaplin is an academic researcher from Baylor University. The author has contributed to research in topics: Combretastatin & Nicotinamide. The author has an hindex of 54, co-authored 184 publications receiving 9360 citations. Previous affiliations of David J. Chaplin include Northwood University & Arizona State University.
Papers
More filters
Journal Article
Intermittent Blood Flow in a Murine Tumor: Radiobiological Effects
TL;DR: It is demonstrated that acute hypoxia results from transient changes in blood perfusion in 500-mg SCC VII tumors, using a new fluorescence-activated cell-sorting technique which facilitates isolation of viable tumor cells as a function of their distance from the blood supply.
Journal Article
Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues
Gillian M. Tozer,Vivien E. Prise,John T. Wilson,R J Locke,Borivoj Vojnovic,Michael R.L. Stratford,Madeleine F. Dennis,David J. Chaplin +7 more
TL;DR: The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system as mentioned in this paper.
Journal ArticleDOI
Vascular‐targeting therapies for treatment of malignant disease
TL;DR: The goal of these approaches is to induce a rapid and catastrophic shutdown of the vascular function of the tumor so that blood flow is arrested and tumor cell death due to the resulting oxygen and nutrient deprivation and buildup of waste products occurs.
Journal Article
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Gillian M. Tozer,Vivien E. Prise,John T. Wilson,Maja Cemazar,Siqing Shan,Mark W. Dewhirst,Paul R. Barber,Borivoj Vojnovic,David J. Chaplin +8 more
TL;DR: The tumor vascular effects of the tubulin destabilizing agent disodium combretastatinA-4 3-O-phosphate (CA-4-P) were investigated in the rat P22 tumor growing in a dorsal skin flap window chamber implanted into BD9 rats, and results suggest a mechanism of action of CA- 4-P in vivo.
Phase I trial of the antivascular agent Combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow
James P. Stevenson,Mark A. Rosen,Weijing Sun,Maryann Gallagher,Daniel G. Hailer,David J. Vaughn,Bruce J. Giantonio,Ross Zimmer,William P. Petros,Michael R.L. Stratford,David J. Chaplin,Scott Young,Mitchell D. Schnall,Peter J. O'Dwyer +13 more
TL;DR: In this paper, the authors investigated escalating doses of Combretastatin A4 (CA4) phosphate administered intravenously to patients with advanced cancer using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies.